$494 Million is the total value of Ghost Tree Capital, LLC's 53 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRAY | VIEWRAY INC | $5,787,000 | -30.6% | 900,000 | 0.0% | 1.17% | -40.1% | |
| AQXP | AQUINOX PHARMACEUTICALS INC | $5,632,000 | +19.7% | 400,000 | 0.0% | 1.14% | +3.3% | |
| CPRX | CATALYST PHARMACEUTICALS INC | $1,315,000 | -38.9% | 550,000 | 0.0% | 0.27% | -47.2% | |
| NABRIVA THERAPEUTICS PLC | $1,006,000 | -15.9% | 200,000 | 0.0% | 0.20% | -27.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ASCENDIS PHARMA A/S - ADR | 30 | Q2 2024 | 11.8% |
| MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
| SAREPTA THERAPEUTICS INC | 25 | Q2 2024 | 9.1% |
| BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
| AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
| SPDR SER TR | 22 | Q1 2024 | 16.9% |
| ARVINAS INC | 19 | Q2 2024 | 4.3% |
| IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
| ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
| SYNDAX PHARMACEUTICALS INC | 18 | Q2 2024 | 6.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-16 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.